ETC
ALNY icon

Exchange Traded Concepts’s Alnylam Pharmaceuticals ALNY Stock Holding History

Exchange Traded Concepts’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
3,640
+388
+12% +$117K 0.01% 900
2026
Q1 		$1.08M Buy
3,252
+891
+38% +$303K 0.01% 784
2025
Q4 		$939K Buy
2,361
+288
+14% +$127K 0.01% 833
2025
Q3 		$945K Sell
2,073
-733
-26% -$298K 0.01% 800
2025
Q2 		$915K Sell
2,806
-909
-24% -$252K 0.01% 714
2025
Q1 		$1M Sell
3,715
-118
-3% -$30.3K 0.02% 561
2024
Q4 		$902K Buy
3,833
+265
+7% +$69.7K 0.02% 602
2024
Q3 		$981K Buy
3,568
+136
+4% +$35.4K 0.02% 519
2024
Q2 		$834K Sell
3,432
-356
-9% -$56.2K 0.02% 501
2024
Q1 		$566K Sell
3,788
-1,625
-30% -$271K 0.01% 640
2023
Q4 		$1.04M Buy
5,413
+2,040
+60% +$347K 0.03% 397
2023
Q3 		$597K Sell
3,373
-4,860
-59% -$927K 0.02% 520
2023
Q2 		$1.56M Sell
8,233
-13,035
-61% -$2.58M 0.04% 311
2023
Q1 		$4.26M Buy
21,268
+13,900
+189% +$2.92M 0.12% 133
2022
Q4 		$1.75M Sell
7,368
-724
-9% -$154K 0.05% 201
2022
Q3 		$1.62M Sell
8,092
-5,161
-39% -$984K 0.05% 174
2022
Q2 		$1.93M Sell
13,253
-279
-2% -$39.6K 0.06% 164
2022
Q1 		$2.21M Buy
13,532
+4,618
+52% +$704K 0.04% 210
2021
Q4 		$1.51M Sell
8,914
-177
-2% -$32.9K 0.03% 278
2021
Q3 		$1.72M Sell
9,091
-1,997
-18% -$375K 0.04% 241
2021
Q2 		$1.88M Buy
11,088
+344
+3% +$50.4K 0.06% 226
2021
Q1 		$1.52M Buy
10,744
+3,368
+46% +$507K 0.06% 228
2020
Q4 		$959K Buy
7,376
+4,629
+169% +$618K 0.04% 234
2020
Q3 		$400K Buy
2,747
+1,272
+86% +$181K 0.02% 348
2020
Q2 		$218K Buy
1,475
+768
+109% +$104K 0.04% 458
2020
Q1 		$77K Buy
707
+323
+84% +$37.3K 0.04% 280
2019
Q4 		$44K Buy
+384
New +$38.3K 0.01% 283

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Exchange Traded Concepts's ALNY Position: Q2 2026 in Review

Exchange Traded Concepts increased its Alnylam Pharmaceuticals (ALNY) stake by 12% in Q2 2026, buying an estimated $117K and bringing the position to 3,640 shares worth $1.1M. The position accounts for 0.01% of the portfolio, ranked #900.

Exchange Traded Concepts first reported a position in ALNY in Q4 2019 and has held it in 27 quarters since. The position peaked at $4.26M in Q1 2023. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Exchange Traded Concepts held 3,640 shares of Alnylam Pharmaceuticals worth $1.1M as of Q2 2026.
  • Exchange Traded Concepts bought 388 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $117K.
  • Alnylam Pharmaceuticals made up 0.01% of Exchange Traded Concepts's portfolio in Q2 2026, its #900 holding.
  • Exchange Traded Concepts first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Exchange Traded Concepts's Alnylam Pharmaceuticals position peaked at $4.26M in Q1 2023.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.